Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5–15 years in Australia
Australia commenced its COVID-19 vaccine program for children aged 12–15 years from July 2021 and for children aged 5–11 years from January 2022 with two primary doses of either Comirnaty (Pfizer–BioNTech BNT162b2, 10 μg for 5–11 years and 30 μg for 12–15 years) or Spikevax (Moderna mRNA-1273, 50 μg for 6–11 years and 100 μg for 12–15 years), 8 weeks apart. A booster dose is recommended for those aged 5–15 years with complex health conditions or severe immunocompromise.
Source: thelancet.com
